EDITION:

Search
Search
Close this search box.

Linneo Health explores trends in medical cannabis

CEO of Linneo Health, Don Bellamy, spoke to Cannabis Wealth about the company’s unique capabilities and future trends in the industry.

Spain-based Linneo Health, which is focused on the research, manufacture and supply of medical cannabis flowers and extracts, recently had its Good Manufacturing Practice (GMP) certification renewed. 

The renewal development will allow Linneo to continue with its research into medical cannabis along with the cultivation and supply of flowers and extracts to pharmaceutical partners.

Linneo’s has a heritage of pharmaceutical expertise, with 90 years of experience operating in the narcotics industry. Its pivot into the medical cannabis industry means it is able to create premium, medical-grade cannabis extracts from its state-of-the-art manufacturing facility based in Murcia, Southern Spain – removing the need for outsourcing. 

“We consider ourselves to be the leading, vertically integrated supplier of primary materials to the cannabis industry. We do everything from cultivation to processing to extraction, and we supply to the specifications of customers strictly for the medical sector in regulated countries,” said Bellamy.

“We have EU GMP certified manufacturing, and we supply cannabis flowers, extracts and products to our partners. We have four hectares – 40,000 square metres – of greenhouse GMP processing capabilities, as well as extraction facilities, and feel that we are the ideal partner for the medical cannabis business.

“There are all sorts of different licenses and we pretty much have them all, including GACP certification for cultivation, GMP processing certification for the finished flower product that we make and we have now we have been certified for good laboratory practices. 

“Inside our facilities, we have a state-of-the-art laboratory where we are able to do, in-house, all of the analysis verifications that are required to certify our product as EU GMP compliant, and compliant for many other geographies around the world. EU regulations are strict, but actually, some countries around the world ask you to test for certain things that the EU doesn’t ask us for – like certain pesticides.”

Advanced flower capabilities 

Linneo has its own database of genetic material which it uses and makes available to its clients around the world.

Through this capability, clients have the option to purchase one of Linneo’s varieties of cannabis which is already available on the market, or, to work with the company to create varieties that are not on the market. 

“We have the capability to cultivate and look after our client’s own genetic material as well. So, if they choose to do so, we are fully equipped to be able to receive the genetics and produce for them.

“I think that the ability to be able to do both of these things I think makes us unique.

“We are not aware of anybody who is a supplier of primary material. Our expertise is in production, processing and primary product packaging at this moment.”

Trends in the medical industry

Bellamy highlighted the increase in popularity of cannabis extracts, and that the company’s heritage means it can leverage chemical infrastructure to apply in the production of cannabis extracts.

Bellamy said: “Our extraction capabilities with our partner will allow us to be able to move forward from dried flowers into oils, which the market is moving to now. There is a lot of interest in extracts with a lot of different companies trying to set themselves up in extracts. 

“You can see, for customers, the obvious appeal of ingesting a medicine in a form which is much more normal and appears more like a controlled medical substance. In the UK market, for example, there is a bit of an issue at the moment with doctors not prescribing and I think that is a lot to do with not being comfortable prescribing cannabis flower and people smoking or vaping them.

“I feel most people trying to get into this business are discovering the high barriers of entry which exist to be able to set up to be able to do this properly. We speak to lots of people who say that they are into extracts or they can produce extracts, but in reality, are not able to produce. 

“The majority of these people at the moment are starting up their operations. We are able to leverage the chemical industrial heritage we have, using a lot of the expertise which has been accumulated over the past to produce a soon-to-be, we hope, GMP-certified extraction.

“I think it’s up to us to find ways to make medical cannabis treatment more normalised for patients and one of the ways to do it is through industrial extracts.”

Looking to Europe and the globe

Linneo supplies medical cannabis products to customers who act in geographies where regulation allows them to. It currently has a European base and a lot of its business is still European-focused, says Bellamy. 

“The fact that we are based in Europe provides us with a really powerful platform to be able to serve European markets. For example, Germany, the UK and beyond. But we don’t limit ourselves only to that. We have customers in Israel and we are looking to expand to the other markets which are in a position to take up.

“We don’t sell at all in our home market, as the market that we happen to operate in doesn’t have a medical cannabis law. So, as a result of that, we don’t supply to Spain – all of our product is exported. 

“Spain is one of those markets around the world that is reviewing what it is thinking on medical cannabis right now, and we would love to support not only the Spanish government but governments around the world to find a way to make these treatments available to patients. 

“At the moment, it’s a question of regulation. There is active debate in Spain, as there is in many other European markets. 

“We hope that they will reach the right decision for patients as it is about giving them a way to access quality medicine as patients in the UK, in Germany, in the Netherlands and Denmark, for example, are able to.”

[activecampaign form=31]

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?